Objectives: To evaluate the long-term safety and efficacy of vibegron 50 mg and 100 mg, a novel b 3 -adrenoreceptor agonist, in Japanese patients with overactive bladder.
Introduction
OAB is defined by the International Continence Society as urinary urgency, usually with urinary frequency and nocturia, with or without urgency urinary incontinence, in the absence of any other pathology. 1 In the general adult population, the prevalence of OAB is 10-20% in Japan, Europe and the USA, [2] [3] [4] but OAB has a significant negative impact on the healthrelated QoL of patients. 5, 6 Anticholinergics have been the first-line treatment for OAB over the past decades. 7 However, many patients discontinue long-term anticholinergic therapy because of limited efficacy and undesired class-related AEs. 8, 9 Much attention has been directed toward b 3 -AR agonists as a new and alternative target of OAB, as the human bladder expresses a high level of b 3 -AR mRNA and b 3 -AR agonist relaxed detrusor smooth muscle.
drug-drug interaction. 15 In a phase 2b placebo-controlled randomized clinical trial, treatments with vibegron 50 mg and 100 mg for 8 weeks in patients with OAB were generally well-tolerated and showed improvements in OAB symptoms (NCT01314872: https://clinicaltrials.gov/ct2/show/ results/NCT01314872). These efficacies were comparable or favorable to those of an active comparator, anticholinergic tolterodine.
The objective of the present study was to evaluate the safety and efficacy of vibegron for long-term treatment of Japanese patients with OAB as a phase 3 study (JapicCTI-152800).
Methods Study design and patients
This was a 1-year (52-week), multicenter, open-label, noncontrolled study in patients with OAB carried out at 25 sites in Japan. The study consisted of a 1-week observation phase and 52-week treatment phase with vibegron. The primary end-point of this study was the safety of vibegron, which was comprehensively evaluated. Male and female patients aged ≥20 years with OAB symptoms for ≥6 months were enrolled. The key exclusion criteria were concurrent diabetes insipidus, urinary tract stone, interstitial cystitis, pelvic organ prolapse, neurogenic bladder, clinically important lower urinary tract obstruction, enuresis, urinary tract infection or a history of recurrent urinary tract infection (≥3 during the past 6 months before screening); a history of pelvic surgery, or neurodegenerative diseases that could affect the lower urinary tract or its nerve supply; indwelling catheter or practiced intermittent self-catheterization; surgery within 6 months before screening to correct stress urinary incontinence or pelvic organ prolapse; bladder training, electrostimulation, magnetic stimulation, biofeedback procedure or pelvic floor muscle training; daily total volume of urine voided ≥3000 mL; or PVR ≥100 mL. Patients who took smooth muscle-relaxant drugs, b 2 -or b 3 -AR agonists, or synthetic antidiuretic hormones were excluded. Concomitant medication with anticholinergics was allowed in this study, but the same regimen was to be maintained during the study. After evaluation for inclusion and exclusion criteria, patient were enrolled in the 1-week observation phase. At the end of the observation phase, once patients met the inclusion criteria related to OAB symptoms (mean frequency of micturitions/day ≥8, either urgency episodes/day ≥1 or urgency incontinence episodes/day ≥1 and the number of urgency incontinence episodes > half of incontinence episodes), patients entered into the treatment phase with vibegron 50 mg. After treatment with 50 mg for 8 weeks, if the investigator judged the efficacy as insufficient without any safety concern and patients agreed with the dose increase, the daily vibegron dose was increased from 50 mg to 100 mg. If the investigators judged no need for a dose increase, patients continued to receive vibegron 50 mg for an additional 44 weeks. After dose adjustment, a dose reduction from 100 mg to 50 mg was allowed only when clinically significant AEs were observed.
The study protocol, informed consent form and other relevant study documentations were approved by the institutional review board at each participating study site. All patients gave written informed consent before initiation of any studyspecific procedure. The study was carried out in accordance with the ethical principles originating in or derived from the Declaration of Helsinki, International Council for Harmonization Good Clinical Practice Guidelines, and locally applicable laws and regulations. The study was designed and carried out by the sponsor (Kyorin Pharmaceutical, Tokyo, Japan) in collaboration with the principal investigators. The study is registered with Japan Pharmaceutical Information Center, number JapicCTI-152800.
Safety and efficacy assessments
Safety was assessed according to the incidence and severity of AEs, clinical test (hematology, biochemistry and urinalysis), vital signs, 12-lead ECG and PVR. The effect of the concomitant use of anticholinergics on safety was assessed. TEAE was defined as an event that first appeared after the start of treatment with vibegron, which was absent before or which worsened relative to the observation phase. For the assessment of efficacy, a 3-day micturition diary was used. Patients were advised to record the precise time and volume of each voided urine. The times of waking up and going to bed, urgency episodes, and incontinence episodes were also recorded. The evaluated efficacy parameters were daily means of micturitions, urgency episodes, urgency incontinence episodes, incontinence episodes and night-time frequency, and mean voided volume per micturition. Changes from baselines (week 0 and week 8) in OAB symptom variables were analyzed at each visit. QoL was evaluated using the KHQ, 17 which was completed at weeks 0, 8, 24 and 52. In addition, patients' satisfaction was assessed at the end of treatment using a self-administered PGI: very much improved, much improved, minimally improved, no change, minimally worse, much worse and very much worse. 18 Patient satisfaction levels were defined as "satisfied," consisting of very much improved, much improved and minimally improved, and "very much satisfied" consisting of very much improved and much improved.
Statistical analysis
Safety analysis was carried out for patients in the SAF, which consisted of patients who took one or more dose of vibegron and had a safety measurement. Efficacy was analyzed in the FAS, which included all patients who took one or more dose of vibegron and had at least an efficacy measurement after the first treatment. AEs were coded using the Medical Dictionary for Regulatory Activities Japanese Edition version 17.1. Changes in continuous variables from baseline were summarized using the descriptive statistics including mean, SD, Min, Med and Max, and categorical variables were described using absolute and relative frequency. The LS mean and the two-sided 95% CI of changes in the response variables from baseline to time of assessment in each group were estimated using a LDA model including adjustment factors: sex, prior treatment for OAB (use/no use of anticholinergics and b 3 -AR agonist) and urgency incontinence (OAB wet and dry). "OAB wet" was defined as patients with one or more mean urgency incontinence/day at baseline, and "OAB dry" as patients with less than one mean urgency incontinence/day at baseline. Statistical tests were carried out under the null hypothesis that the change difference was zero (0) using the LDA model. Baselines were defined as week 0 and week 8. P-value <0.05 was considered statistically significant. A sample size of 160 was selected to allow the assessment of 100 patients or more completed for 52 weeks treatment. All analyses were carried out using SAS software version 9.4 for Windows (SAS Institute, Cary, NC, USA).
Results

Patient disposition and baseline characteristics
The study was carried out at 25 sites in Japan from March 2015 to June 2016. A total of 169 patients received one or more doses of vibegron (Fig. 1) . The number of patients of the vibegron 50 mg (dose-retained) group was 118 (69.8%) and vibegron 100 mg (dose-increased) group was 51 (30.2%). The proportion of patients who completed the study was 86.4% (102/118) in the vibegron 50 mg group and 94.1% (48/51) in the vibegron 100 mg group. The SAF population consisted of 167 patients after excluding two patients because of double entries in different study sites. The FAS consisted of 166 patients after excluding one patient in the SAF due to unavailability of efficacy data (n = 1). Patient characteristics and baseline of the efficacy variables at week 0 in the FAS population are presented in Table 1 . There were no significant differences in patient characteristics between the two groups. However, the baseline of OAB symptom variables including daily means of micturitions, urgency episodes, urgency incontinence episodes and incontinence episodes, and the proportion of OAB wet in the vibegron 100 mg group were significantly higher than those in the vibegron 50 mg group. Anticholinergics, such as solifenacin, fesoterodine, imidafenacin and propiverine, were used in combination with vibegron in 34 (20.5%) patients: 25 (21.6%) patients in the 50 mg group and nine (17.6%) patients in the 100 mg group. Adherences of all patients to the treatment were ≥75% and mean AE SD exposure duration to vibegron was 338.6 AE 76.0 days (range 25-371 days).
Safety
The overall incidence of any TEAEs was 55.1% (92/167), and drug-related TEAEs was 16.2% (27/167; Table 2 ). The AEs were coded using the MedDRA/J version 17.1.
incidence of any AEs was similar between the vibegron 50 mg (dose-retained) and 100 mg (dose-increased) groups, although the incidence of cystitis and residual urine volume increased in the vibegron 50 mg group were numerically higher than in the 100 mg group. Common drug-related TEAEs were residual urine volume increased (4.3%, 5/116), dry mouth (2.6%, 3/116), cystitis (2.6%, 3/116) and constipation (1.7%, 2/116) in the vibegron 50 mg group, and dry mouth (3.9%, 2/51) and constipation (3.9%, 2/51) in the vibegron 100 mg group. Almost all the TEAEs were mild or moderate in intensity. Severe TEAEs, which only occurred in the vibegron 50 mg group, were angina pectoris, Prinzmetal angina, fall and cerebral infarction, but these were not considered related to vibegron, except cerebral infarction. One-third of TEAEs (32.9%) were reported during the first 12 weeks after the start of treatment and decreased time-dependently after week 12. One death due to fall was reported in the present study. Five SAEs other than death were reported in five patients in the vibegron 50 mg group: angina pectoris, Prinzmetal angina, cerebral infarction, intervertebral disc protrusion and vertigo positional, but were not reported in the vibegron 100 mg group. The investigator considered that all SAEs, except cerebral infarction, had no relationship with vibegron because of a non-correlation between the AE onset and the administration of the drug. All SAEs became less severe or recovered with appropriate treatments, except death. TEAEs leading to permanent discontinuation of the treatment occurred in six events in six patients: fall, Prinzmetal angina, cerebral infarction and angina pectoris (each one), and residual urine volume increased (n = 2). There were no notable differences in the incidence of drug-related TEAEs between combination with (23.5%) and without (14.3%) anticholinergics. However, dry mouth, increased residual urine volume and constipation, which are TEAEs related to anticholinergics, are relatively higher in patients with concominant use of anticholinergics. The incidence of dry mouth, increased residual urine volume and constipation was 5.9% (2/34), 11.8% (4/34) and 2.9% (1/34) in patients taking anticholinergic, and 2.3% (3/133), 0.8% (1/133) and 2.3% (3/133) in patients not taking anticholinergic, respectively. No clinically significant changes in vital signs were observed over time, as shown in Figure 2 . Abnormal ECG was found in 3.0% (5/166) of patients, but the investigator reported no relationship with vibegron. No notable changes in clinical tests (hematology, biochemistry and urinalysis) and PVR were observed during the study. The two patients who discontinued due to the increased residual urine volume (TEAE) were women with the concomitant use of anticholinergics. The increased PVR volumes were 365 mL (baseline 69 mL) and 184 mL (baseline 72 mL), respectively. In patients with the concomitant use of anticholinergics, PVR slightly increased from baseline at week 4 (9.1 mL); however, the increase was not clinically significant and no further increase was observed thereafter. The increase of PVR at week 52 was just 4.1 mL.
Efficacy
Significant changes from baseline (week 0) at week 52 were observed in all OAB symptom variables (Table 3) . These significant changes from baseline (week 0) were found at week 4 and continued through the study (Fig. 3) . Even in patients whose dose was increased due to insufficient efficacy judged by the investigators, the OAB symptom variables including micturition, urgency, urgency incontinence, incontinence and night-time frequency were significantly improved by treatment with vibegron 50 mg at week 8. In addition, the vibegron dose increase to 100 mg resulted in significant improvement (changes from week 8 to week 12; Fig. 3) . In QoL assessments, treatment with vibegron significantly reduced the LS mean of the KHQ domain scores from baseline at week 52, except for general health perception ( Table 4 ). The proportions of patients that reported "satisfied" and "very much satisfied" in the PGI were 91.0% (151/166) and 71.1% (118/166), respectively ( Table 5 ).
Discussion
The present 1-year long study showed that long-term vibegron 50 mg and 100 mg treatments were safe, well-tolerated and clinically useful in patients with OAB. In this study, the most frequent drug-related TEAEs were dry mouth, residual urine volume increased, constipation and cystitis. These are well known as class-related AEs of anticholinergics, but the incidence of AEs of vibegron was much lower than those reported for anticholinergics. 19 No novel, clinically significant AEs were seen in this long-term treatment with vibegron, referring to the phase 2b study. AEs observed after the dose increase to 100 mg were 37.3% (19/51), whereas in the vibegron 50 mg group, AEs were 47.3% (52/110), suggesting no noteworthy differences in safety profiles between the 50 mg and 100 mg groups of vibegron. Because four severe TEAEs were observed only in 50 mg, the possibility of an ordering .001 †Statistical test under the null hypothesis that the change from week 0 to week 52 was 0. ‡Statistical test under the null hypothesis that the change from week 8 to week 52 was 0. §The number of episodes at baseline was not 0. effect was not completely ruled out. However, causal relationships with the study drug were denied in three cases. Therefore, we considered that it was not due to an ordering effect. Furthermore, there were no differences in safety between combination with and without anticholinergics. This suggests that vibegron can be safely used with the combination of anticholinergics. Significant improvement changes from baseline in all OAB symptom variables were seen by the 8th week of the treatment with vibegron 50 mg, and were maintained throughout the study. The investigators judged that the efficacies of vibegron 50 mg in 51 patients were insufficient and a dose increase to 100 mg resulted in significant improvement. It should be noted that the baselines of OAB symptoms at week 0 in the vibegron 100 mg group were significantly more severe than those of the vibegron 50 mg group, suggesting that vibegron 100 mg might be useful for treatment of patients with severe OAB. Significant improvement in urgency incontinence episodes would be a determining cause of improvement in the KHQ domain scores, as reported in other studies. 20, 21 OAB is a chronic condition and typically requires long-term treatment, and high persistence and adherence to therapy are essential for the management of OAB. 22 Although anticholinergics are the first-line pharmacological treatment for OAB, persistence with prescribed therapy is very low due to poor efficacy and tolerability. 23 Objective measures in clinical trials have poorly correlated with patient-related outcome measures, therefore the improvement in patient-related outcome is thought to be important for the evaluation of clinical significance. 19 In the present study, vibegron treatment for week 52 significantly improved OAB symptoms and improved the patients' satisfactions in PGI measurement. It is noteworthy that long-term treatment with vibegron satisfied not only the objective, but also the subjective measurements for the patients with OAB. In addition, high satisfactions were obtained when the dose was increased to 100 mg in patients who did not respond well to the 50 mg dose, suggesting that dose escalation of vibegron is beneficial for achieving further satisfaction of the patients together with improvement of OAB symptoms. The present study had some limitations. The first was the lack of placebo control. A marked placebo effect on treatment outcomes in OAB symptoms has been reported in many double-blind, placebo-controlled, randomized trials. 24 The true effectiveness and safety profile could not be determined in the present study, and particularly, the efficacy outcomes might be overestimated. Meanwhile, the robust effectiveness of vibegron for the treatment of OAB has been elucidated in the previous placebo-controlled study. Second, the proportions of elderly patients and male patients in the present study were lower than those in the real world. 1 Finally, the number of patients, particularly the number of concomitant use of anticholinergics, was relatively small to assess safety. Further long-term studies, including a postmarketing study in routine clinical practice evaluating the safety and effectiveness of vibegron in a large number of patients, are required.
In conclusion, vibegron 50 mg and 100 mg have favorable safety profiles for the 52-week treatment. Vibegron improved OAB symptoms and QoL, and a dose increase to 100 mg improved OAB symptoms without increasing AEs in those patients who did not respond well to vibegron 50 mg. Vibegron could provide a promising treatment for OAB using monotherapy with the usual dose of 50 mg, with dose escalation to 100 mg if efficacy is insufficient.
